Eli Lilly & Co.
LLYEli Lilly & Co. is a global pharmaceutical company founded in 1876, focused on developing innovative medicines in areas such as oncology, neuroscience, diabetes, and immunology. The company is known for its research-driven approach and has a strong portfolio of prescription drugs and biologics aimed at improving patient health worldwide.
Dividend History
Investors can expect a dividend payout of $1.73 per share, scheduled to be distributed in 54 days on September 10, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 10, 2026 | $1.73 | 2026-08-14 | 2026-08-14 |
| June 10, 2026 | $1.73 | 2026-05-15 | 2026-05-15 |
| March 10, 2026 | $1.73 | 2026-02-13 | 2026-02-13 |
| December 10, 2025 | $1.50 | 2025-11-14 | 2025-11-14 |
| September 10, 2025 | $1.50 | 2025-08-15 | 2025-08-15 |
Dividends Summary
- Consistent Payer: Eli Lilly & Co. has rewarded shareholders with 91 dividend payments over the past 22 years.
- Total Returned Value: Investors who held LLY shares during this period received a total of $62.02 per share in dividend income.
- Latest Payout: The most recent dividend of $1.73/share was paid 38 days ago, on June 10, 2026.
- Yield & Schedule: LLY currently pays dividends quarterly with an annual yield of 0.57%.
- Dividend Growth: Since 2004, the dividend payout has grown by 387.3%, from $0.35 to $1.73.
- Dividend Reliability: LLY has maintained or increased its dividend for 91 consecutive payments.
Company News
While Eli Lilly's GLP-1 weight-loss drugs (Mounjaro and Zepbound) account for nearly two-thirds of revenues with strong growth, the company is strategically using profits from these drugs to build a diversified pipeline in immunology, oncology, and neuroscience through acquisitions like AtaiBeckley and Ventyx Biosciences. Non-weight-loss drugs ar...
Novo Nordisk's oral Wegovy launch has regained market share in the GLP-1 weight-loss drug market, capturing ~89% of oral weight-loss medication prescriptions in the U.S. However, Eli Lilly's Foundayo has potential advantages including fewer food restrictions and upcoming label expansions for multiple indications. Both companies remain well-positi...
Atlas Healthcare Fund, managed by VST Capital, showcased its track record of early conviction investments in healthcare, with notable positions in Eli Lilly (entered at $350, now trading above $1,200), Alnylam Pharmaceuticals, TransMedics Group, and Inari Medical. The fund has delivered cumulative net returns of +1,720.9% since inception in Janua...
AtaiBeckley shares surged 33.40% after pharmaceutical giant Eli Lilly agreed to acquire the mental health-focused biotechnology company for $6.75 per share in cash, plus up to $2.50 per share in milestone payments. The total deal valuation could reach approximately $3.8 billion if all conditions are met. The acquisition is expected to close in Q3...
The iShares Global Healthcare ETF (IXJ) outperformed the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) over the past five years, delivering stronger total returns (1.50% dividend yield vs. 0.70%), lower volatility (beta of 0.56 vs. 0.78), and a shallower maximum drawdown. While both funds charge identical 0.40% expense ratios, IXJ's market-...
